Xiao-Wei Jia Selected Research

hepatic stimulator substance

1/2018	Lack of hepatic stimulator substance expression promotes hepatocellular carcinoma metastasis partly through ERK-activated epithelial-mesenchymal transition.
12/2017	Augmenter of liver regeneration potentiates doxorubicin anticancer efficacy by reducing the expression of ABCB1 and ABCG2 in hepatocellular carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiao-Wei Jia Research Topics

Disease

2	Hepatocellular Carcinoma (Hepatoma) 01/2018 - 12/2017
2	Neoplasm Metastasis (Metastasis) 01/2018 - 12/2017
1	Papillomavirus Infections 01/2018
1	Mouth Neoplasms (Oral Cancer) 01/2018
1	Carcinoma (Carcinomatosis) 01/2018
1	Neoplasms (Cancer) 12/2017
1	Head and Neck Neoplasms (Head and Neck Cancer) 06/2017
1	Periodontal Diseases (Periodontal Disease) 05/2017
1	Periodontitis 01/2017

Drug/Important Bio-Agent (IBA)

2	hepatic stimulator substanceIBA 01/2018 - 12/2017
1	Codon (Codons)IBA 01/2018
1	Member 2 Subfamily G ATP Binding Cassette TransporterIBA 12/2017
1	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2017
1	Interleukin-10 (Interleukin 10)IBA 06/2017
1	Interleukin-1beta (Interleukin 1 beta)IBA 05/2017
1	Interleukin-4 Receptors (Interleukin 4 Receptor)IBA 01/2017
1	Interleukin-4 (Interleukin 4)IBA 01/2017